- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 639391, 5 pages
The Effect of Ranitidine on Olanzapine-Induced Weight Gain
1Clinical Psychiatry Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran
2Neuroscience Research Center, Department of Statistics & Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran
3Department of Public Health Sciences, WHO Collaborating Center for Safe Communities, Karolinska Institute, 171 76 Stockholm, Sweden
Received 6 April 2013; Revised 24 May 2013; Accepted 27 May 2013
Academic Editor: Akito Tanoue
Copyright © 2013 Fatemeh Ranjbar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. H. Hosseini and A. K. Polonowita, “Priapism associated with olanzapine,” Pakistan Journal of Biological Sciences, vol. 12, no. 2, pp. 198–200, 2009.
- B. Sadock and V. Sadock, Synopsis of Psychiatry, Lippincott, Philadelphia, Pa, USA, 1st edition, 2007.
- S. Ghaffari, S. E. Hashemi, and H. Atabaki, “The national financial burden of hospitalization of diabetes in Iran,” Journal of Clinical Research & Governance, vol. 1, pp. 16–21, 2012.
- S. Gupta, T. Droney, S. Al-Samarrai, P. Keller, and B. Frank, “Olanzapine: weight gain and therapeutic efficacy,” Journal of Clinical Psychopharmacology, vol. 19, no. 3, pp. 273–276, 1999.
- D. C. Goff and A. E. Evins, “Negative symptoms in Schizophrenia: neurobiological models and treatment response,” Harvard Review of Psychiatry, vol. 6, no. 2, pp. 59–77, 1998.
- S. G. Siris, D. P. van Kammen, and J. P. Docherty, “Use of antidepressant drugs in schizophrenia,” Archives of General Psychiatry, vol. 35, no. 11, pp. 1368–1377, 1978.
- P. Cavazzoni, Y. Tanaka, S. M. Roychowdhury, A. Breier, and D. B. Allison, “Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial,” European Neuropsychopharmacology, vol. 13, no. 2, pp. 81–85, 2003.
- A. López-Mato, J. Rovner, G. Illa, A. Vieitez, and O. Boullosa, “Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration,” Vertex, vol. 14, no. 52, pp. 85–96, 2003.
- S. W. Andersen, D. B. Clemow, and S. A. Corya, “Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder,” Journal of Clinical Psychiatry, vol. 66, no. 11, pp. 1468–1476, 2005.
- K. L. Davis, R. S. Kahn, G. Ko, and M. Davidson, “Dopamine in schizophrenia: a review and reconceptualization,” American Journal of Psychiatry, vol. 148, no. 11, pp. 1474–1486, 1991.
- S. Hajebrahimi, A. Mostafaie, and H. Sadeghi-Bazargani, “Evidence for the future—designing a clinical trial,” Indian Journal of Urology, vol. 27, no. 4, pp. 494–497, 2011.
- H. Sadeghi-Bazargani and M. Sedghipour, “Setting the objectives and hypotheses in randomized clinical trials: notices for clinicians and pharmacologists,” International Journal of Pharmacology, vol. 8, no. 6, pp. 475–482, 2012.
- D. E. Johnson, H. Yamazaki, K. M. Ward et al., “Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia,” Diabetes, vol. 54, no. 5, pp. 1552–1558, 2005.
- R. E. Kast and E. L. Altschuler, “Current drugs available now for interleukin-6 suppression as treatment adjunct in glioblastoma: anakinra, aprepitant, mirtazapine and olanzapine,” International Journal of Cancer Research, vol. 2, no. 4, pp. 303–314, 2006.
- U. Eder-Ischia, C. Ebenbichler, and W. W. Fleischhacker, “Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism,” Essential Psychopharmacology, vol. 6, no. 2, pp. 112–117, 2005.
- E. K. Hester and M. R. Thrower, “Current options in the management of olanzapine-associated weight gain,” Annals of Pharmacotherapy, vol. 39, no. 2, pp. 302–310, 2005.
- T. Doi, T. Sakata, H. Yoshimatsu et al., “Hypothalamic neuronal histamine regulates feeding circadian rhythm in rats,” Brain Research, vol. 641, no. 2, pp. 311–318, 1994.
- S. S. M. Assunção, S. I. Ruschel, L. D. C. R. Rosa et al., “Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine,” Revista Brasileira de Psiquiatria, vol. 28, no. 4, pp. 270–276, 2006.
- T. Baptista, J. Martínez, A. Lacruz et al., “Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial,” Canadian Journal of Psychiatry, vol. 51, no. 3, pp. 192–196, 2006.
- T. Baptista, E. Uzcátegui, N. Rangel et al., “Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study,” Psychiatry Research, vol. 159, no. 1-2, pp. 250–253, 2008.
- C.-U. Pae, J.-J. Kim, K.-U. Lee et al., “Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study,” Human Psychopharmacology, vol. 18, no. 6, pp. 453–456, 2003.
- M. Poyurovsky, V. Tal, R. Maayan, I. Gil-Ad, C. Fuchs, and A. Weizman, “The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study,” European Neuropsychopharmacology, vol. 14, no. 4, pp. 332–336, 2004.
- E. Sacchetti, L. Guarneri, and D. Bravi, “H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients,” Biological Psychiatry, vol. 48, no. 2, pp. 167–168, 2000.
- R.-R. Wu, J.-P. Zhao, X.-F. Guo et al., “Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study,” American Journal of Psychiatry, vol. 165, no. 3, pp. 352–358, 2008.
- C. Bushe, J. Sniadecki, A. J. Bradley, and V. P. Hoffmann, “Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia,” Journal of Psychopharmacology, vol. 24, no. 7, pp. 1001–1009, 2010.
- B. Arranz, L. San, R. M. Dueñas et al., “Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients,” Human Psychopharmacology, vol. 22, no. 1, pp. 11–15, 2007.
- J. Karagianis, V. P. Hoffmann, B. Arranz et al., “Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain,” Human Psychopharmacology, vol. 23, no. 4, pp. 275–281, 2008.
- E. M. van der Zwaal, M. C. M. Luijendijk, R. A. H. Adan, and S. E. la Fleur, “Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution,” European Journal of Pharmacology, vol. 585, no. 1, pp. 130–136, 2008.
- M. Atmaca, M. Kuloglu, E. Tezcan, and B. Ustundag, “Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain,” Human Psychopharmacology, vol. 18, no. 6, pp. 457–461, 2003.
- M. Atmaca, E. Tezcan, and B. Ustundag, “Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain,” Journal of Psychiatric Research, vol. 41, no. 1-2, pp. 74–79, 2007.
- T. Baptista and S. Beaulieu, “Body weight gain, insulin, and leptin in olanzapine-treated patients,” Journal of Clinical Psychiatry, vol. 62, no. 11, pp. 902–904, 2001.